Compare Fox Corp Class B (FOX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Medpace Holdings Inc — how do they compare? Fox Corp Class B trades at $59.02 (market cap $25.36B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Fox Corp Class B is the larger of the two by market cap, and Fox Corp Class B pays a 1.02% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Medpace Holdings Inc for 14 Days on average.
| FOX | MEDP | |
|---|---|---|
Market Cap | $25.36B | $16.82B |
Volume | 886,620 | 223,093 |
Sector | Media | Health |
52-Week High | $67.76 | $630.19 |
52-Week Low | $44.39 | $393.42 |
Typical Hold Time | 75 Days | 14 Days |
Enterprise Value | $28.72B | $16.44B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a net income margin of 13.88% in 2025, highlight robust profitability. The company maintains solid cash flow and a healthy balance sheet with $5.35B in cash. Analyst consensus is a Buy with a $84.75 price target, though technical indicators show resistance near $57.
The stock presents a value opportunity with a P/E of 14.59 and P/S of 1.44, supported by earnings growth. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical trends. Upside potential exists if the company meets Q3 2026 EPS expectations of 2.06, but investors should monitor cash flow trends and competitive pressures in the media sector.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
